On page 136 in Table 3, the clinical trial for acute renal failure has been attributed to Quark/Pfizer when it should be attributed to Quark alone. In addition, the authors would like to clarify that, following a Phase I/II trial in patients with wet age-related macular degeneration, the siRNA drug candidate PF-4523655 (RTP801i-14) is now being studied in a Phase II trial for diabetic macular oedema conducted by Pfizer in collaboration with Quark.
Additional information
The online version of the original article can be found at 10.1038/nrd2742
Rights and permissions
About this article
Cite this article
Whitehead, K., Langer, R. & Anderson, D. Erratum: Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8, 516 (2009). https://doi.org/10.1038/nrd2919-c1
Issue Date:
DOI: https://doi.org/10.1038/nrd2919-c1
